An evaluation study to assess the potential use of Renamil (formerly named Ren-o-mil) for patients with chronic renal failure

Abstract

Background: Renamil has been formulated as a milk substitute/nutritional supplement for renal patients. This 5-month study of 16 selected patients, six with chronic renal failure, six on chronic intermittent haemodialysis and four on continuous ambulatory peritoneal dialysis (CAPD), was carried out to evaluate the potential use of Renamil within these patient groups. Methods: An initial dose was recommended and advice provided on the use of Renamil. Palatability and acceptability of the product were assessed by questionnaire. The patients' serum biochemistry and nutritional status were monitored. The prescription of Renamil was adjusted during the trial according to individual dietary requirements, fluid allowance and product tolerance. Results: Ten patients (62.5%) completed the trial. Palatability and ease of use were important factors. Renamil was used in a wide variety of ways and compared favourably with other milk substitutes/nutritional supplements. Conclusions: Our findings suggest that Renamil (until recently named Ren-o-mil) does have a role in the nutritional support of renal patients. It is the only milk substitute that has been specifically designed for renal patients. Its formulation makes it useful for the majority of pre-dialysis patients, a smaller but significant proportion of haemodialysis patients, but only a limited number of patients on CAPD.